APC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63)
抗體來源(Source)
Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
應(yīng)用(Application)
Flow Cytometry (Evaluation of the expression of CD19 on Human cells).
克隆號(Clone)
FMC63
種屬(Species)
Mouse
亞型(Isotype)
Mouse IgG2a | Mouse kappa
特異性(Specificity)
This product is a specific antibody specifically reacts with CD19 protein.
種屬反應(yīng)性(Reactivity)
Human
免疫原(Immunogen)
Human prolymphocytic leukaemia cell line JVM3.
偶聯(lián)(Conjugate)
APC
Excitation Wavelength: 640 nm
Emission Wavelength: 661 nm
同型對照(Isotype Control)
The Isotype control is sold separately and you can search for Cat. No. DNP-AFM487 for product information.
推薦稀釋比(Recommended Dilution)
1:20
制劑(Formulation)
Supplied as 0.2 μm filtered solution in PBS, 0.2% BSA, 0.03% Proclin 300, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
存儲(Storage)
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Store at 2-8 °C for 12 months.

背景(Background)
B淋巴細(xì)胞抗原CD19也稱為CD19(分化簇19),是一種單程I型膜蛋白,含有兩個(gè)Ig樣C2型(免疫球蛋白樣)結(jié)構(gòu)域。CD19在濾泡樹突細(xì)胞和B細(xì)胞上表達(dá)。事實(shí)上,它存在于B細(xì)胞上,從發(fā)育過程中最早可識別的B譜系細(xì)胞到B細(xì)胞母細(xì)胞,但在成熟為漿細(xì)胞時(shí)丟失。它主要作為與CD21和CD81結(jié)合的B細(xì)胞共受體。激活后,CD19的細(xì)胞質(zhì)尾部被磷酸化,導(dǎo)致Src家族激酶結(jié)合并募集PI-3激酶。與T細(xì)胞一樣,幾個(gè)表面分子形成抗原受體,并在B淋巴細(xì)胞上形成復(fù)合物。(幾乎)B細(xì)胞特異性CD19磷酸糖蛋白就是這些分子之一。其他是CD21和CD81。這些表面免疫球蛋白(sIg)相關(guān)分子促進(jìn)信號轉(zhuǎn)導(dǎo)。在活的B細(xì)胞上,模擬外源性抗原的抗免疫球蛋白抗體使CD19與sIg結(jié)合并內(nèi)化。相反的過程尚未得到證實(shí),這表明這種受體復(fù)合物的形成是由抗原誘導(dǎo)的。這種分子關(guān)聯(lián)已被化學(xué)研究證實(shí)。CD19突變與以抗體產(chǎn)生減少為特征的嚴(yán)重免疫缺陷綜合征有關(guān)。CD19已被證明與CD81、CD82、補(bǔ)體受體2和VAV2相互作用。
關(guān)鍵字: CD19;CD19抗體;單克隆CD19;百普賽斯;ACRO;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。